| Karsten Munk Knudsen |
Karsten Munk Knudsen is currently the Chairman at NNE A, Novo Nordisk Region Aameo & Latam A, Novo Nordisk Region Europe A, Novo Nordisk North America Operations A, and Director at Hempel A. He previously worked as the Principal at A.P. Møller-Mærsk A, Financial Analyst at Nykredit Bank A, Member-Supervisory Board at Innate Pharma SA, VP-Finance & Information Technology at Novo Nordisk, Inc. from 2010 to 2014, and Head-Finance at NNIT A. Mr. Knudsen obtained a graduate degree from the University of Aarhus in 1998. |
| Maziar Mike Doustdar |
Maziar Mike Doustdar is currently the Director at Orion Oyj and the Managing Director at Novo Nordisk Health Care AG. He previously worked as the Executive Vice President-International Operations at Novo Nordisk A from 1992 to the present. Before that, he was a Member at the European Federation of Pharmaceutical Industries & Assns from 2016 to 2021. He also held the position of EVP & Head-International Operations at Novo Nordisk Ltd. Mr. Doustdar completed his undergraduate degree at Webster University in 1994. |
| Marcus Schindler |
Marcus Schindler's career history includes current and former positions as well as his education history. Currently, he is the Chief Scientific Officer & Executive VP-Research at Novo Nordisk A since 2021. Previously, he worked as the Head-Research at The Oxford. From 2018 to 2021, he was a Member-Supervisory Board at Innate Pharma SA. He also served as the Head-Research at Prosidion Ltd. and as the Vice President & Head-Cardiovascular at AstraZeneca A. In terms of education, Dr. Schindler obtained a doctorate degree from the University of Cambridge in 1997 and a graduate degree from the University of Gottingen in 1994. |
| Stephen Gough |
Stephen Gough has worked as the Global Chief Medical Officer at Novo Nordisk A since 2015. |
| Helge Lund |
Helge Lund is currently the Chairman at BP Plc, BP Canada Energy Group ULC, Novo Nordisk A, BP Oil Australia Pty Ltd., Inkerman Holding AS, Tjaldur P, Belron Group SA, Clayton Dubilier & Rice LLC, International Crisis Group, European Round Table of Industrialists, and BP Technology Ventures Ltd. He is also a Trustee at The International Crisis Group (United States). Previously, Mr. Lund served as the Chief Executive Officer & Executive Director at BG Group Ltd. from 2015 to 2016. He was the President & Chief Executive Officer at Equinor ASA from 2004 to 2014. He also held the position of Chief Executive Officer-Oil Services at Schlumberger GmbH from 2016 to 2018 and President & Chief Executive Officer at Akastor ASA from 2002 to 2004. Additionally, he served as Chairman at BP America, Inc. and Independent Non-Executive Director at Nokia Oyj from 2011 to 2014. He was an Independent Non-Executive Director at Schlumberger NV from 2016 to 2018 and an Independent Director at Novo Nordisk A from 2014 to 2015. He has also held various other directorial positions. Mr. Lund holds an MBA from INSEAD, which he obtained in 1991. He also graduated from the Norwegian School of Economics & Business Administration in 1987. |
| Henrik Ehlers Wulff |
Henrik Ehlers Wulff is currently the Chairman at Novo Nordisk Production SAS and Novo Nordisk. Pharmatech A. He is also an Independent Director at Ambu A, a Director at Grundfos Holding A, and a Director at Grundfos Americas Corp. In 2019, he became the Executive VP-Product Supply, Quality & IT at Novo Nordisk A. Previously, he held positions as a Director at NNE A and NNE Pharmaplan A. Mr. Wulff graduated from the Technical University of Denmark in 1995. |
| Lars Fruergaard Jørgensen |
Lars Fruergaard Jørgensen currently works at Novo Nordisk A, as President & Chief Executive Officer from 2017, Novo Nordisk Ltd., as President & Chief Executive Officer from 2004, Harno Invest A, as Chairman, and European Federation of Pharmaceutical Industries & Assns, as Vice President from 2021. Mr. Jørgensen also formerly worked at Carlsberg A, as Vice Chairman-Supervisory Board, Carlsberg Breweries A, as Vice Chairman-Supervisory Board, NNE Pharmaplan A, as Vice Chairman, ZymoGenetics, Inc., as Director in 2010, NNIT A, as Director from 2005 to 2015, Innate Pharma SA, as Member-Supervisory Board from 2007 to 2013, and Novo Nordisk SAS, as Vice President-Finance & Information Technology in 2004. Mr. Jørgensen received his graduate degree in 1991 from the University of Aarhus. |
| Andreas Fibig |
Andreas Fibig is currently the Chairman at German American Chamber of Commerce, Inc. and the Chairman at Max Planck Institute For Infection Biology. He is also an Independent Director at Novo Nordisk A, ExlService Holdings, Inc., Indigo Ag, Inc., Montai Health, Inc., and Evodiabio ApS. Additionally, he holds the position of Executive Director at World Business Council for Sustainable Development and Director at European Federation of Pharmaceutical Industries & Assns. Mr. Fibig's former positions include Chairman & Chief Executive Officer at International Flavors & Fragrances, Inc., Chairman at Bayer Pharma AG, President & Chairman-Management Board at Bayer HealthCare Pharmaceuticals, Inc., Director-Sales & Marketing at Bayer Schering Pharma AG, Independent Director at Bunge Ltd., Senior VP-US Pharmaceutical Operations Group at Pfizer Inc., Principal at Boehringer Ingelheim GmbH, President-Market at Pharmacia GmbH, and Member-Supervisory Board at Verband Forschender Arzneimittelhersteller eV. He obtained his undergraduate degree from Hochschule für Wirtschaft und Recht Berlin in 1982. |
| Laurence Debroux |
Laurence Debroux is currently an Independent Director at Novo Nordisk A, a Director at École des Hautes Études Commerciales de Paris, the Chief Financial Officer & Director at Dibevit Import Srl, a Director at JCDecaux Bollore Holding SAS, a Director at Bpifrance Participations SA, and an Independent Non-Executive Director at EXOR NV. Ms. Debroux previously served as an Independent Director at Solvay SA, the Chief Financial Officer & Director at Heineken NV, a Director at APG SGA SA, a Director at Juventus Football Club SpA, an Independent Director at Natixis SA, a Director at Média Aéroports de Paris SAS, the Chief Financial & Administrative Officer at JCDecaux SE, the Chief Financial Officer at Heineken Holding NV, and the Chief Financial & Strategic Officer at Sanofi SA. Ms. Debroux also served as a Member-Supervisory Board at MediaKiosk SAS. Ms. Debroux graduated from École des Hautes Études Commerciales de Paris in 1992. |
| Christina Law |
Christina Law currently works at Novo Nordisk A, as Independent Director from 2022, Air Liquide SA, as Independent Director from 2023, Raintree Group Ltd., as Director from 2019, Insead Business School, as Director from 2016, Raintree Investment Pte Ltd., as Director from 2019, and La Fondation Des Champions, as Director. Ms. Law also formerly worked at Air Liquide Tunisie SA, as Independent Director, General Mills, Inc., as Group President-Asia from 2012 to 2019, Johnson & Johnson, as Vice president, and Proctor & Gamble, as Head-Marketing from 1992 to 2003. Ms. Law received her undergraduate degree in 1988 from the University of Hong Kong and Masters Business Admin degree in 1991 from INSEAD. |
| Martin W. MacKay |
Martin W. MacKay is the founder and currently holds the position of Chairman & Chief Executive Officer at Rallybio LLC, which was founded in 2018. He is also the Executive Chairman at Rallybio Corp., founded in 2018. In addition to his founding positions, Dr. MacKay currently serves as the Chief Executive Officer at Calyx Group Ltd. (Ireland) and Rallybio Holdings LLC. He is also a Director at Charles River Laboratories International, Inc., an Independent Director at Charles River Laboratories, Inc., and an Independent Director at Novo Nordisk A since 2018. Dr. MacKay has held former positions as the Chief Executive Officer at Vecta Software Corp. Ltd., Neverfail, Inc., and Neverfail Ltd. He was also a Director at Encysive Pharmaceuticals, Inc. in 2008. Additionally, he has served as the Operations Director at The Dun & Bradstreet Corp. and Director-Business Development at NorthgateArinso, Inc. Dr. MacKay was an Independent Director at 5:01 Acquisition Corp. from 2020 to 2022. He held the position of Senior Vice President-Worldwide Development at Pfizer Inc. from 1995 to 2009 and President-Research & Development at AstraZeneca PLC from 2010 to 2013. From 2013 to 2017, he was the Global Head-Research & Development at Alexion Pharmaceuticals, Inc. Dr. MacKay has also held positions at VeriSign, Inc., BASF Performance Products Ltd. (United Kingdom), New Leaf Venture Partners LLC, Pfizer (St. Louis), CRI Worldwide LLC, PeopleSoft USA, Inc., Accenture LLC, Ciba-Geigy Pharmaceuticals, and Beecham Pharmaceuticals (UK). Dr. MacKay obtained a doctorate degree from The University of Edinburgh in 1984 and an undergraduate degree from Heriot-Watt University in 1979. |
| Sylvie Louise Grégoire |
Sylvie Louise Grégoire is the founder and currently holds multiple positions. She is the Executive Chairman of EIP Pharma, Inc. which was founded in 2010. She is also the Chairman of Corvidia Therapeutics, Inc. since 2016, an Independent Director at Revvity, Inc. since 2015, an Independent Director at Novo Nordisk A since 2015, a Director at F2G Ltd., a Director at Revvity BV, a Director at CervoMed, Inc. since 2023, and a Member-Supervisory Board at Shire Orphan Therapies GmbH. In her former positions, Dr. Grégoire served as the President, CEO & Executive Director of GlycoFi, Inc. from 2004 to 2005. She was the Chairman of Metriopharm AG and the Executive Chairman of IDM Pharma, Inc. from 2005 to 2007. She also served as an Independent Director at Cubist Pharmaceuticals LLC from 2006 to 2011. Additionally, she held various director positions at Thallion Pharmaceuticals, Inc., CellCarta Biosciences, Inc., Vifor Pharma Management AG, Novo Nordisk Ltd., and Galenica AG. She was the Executive Vice President-Technical Operations at Biogen MA, Inc. from 2001 to 2003 and the Executive Vice President-Business Development at Biogen, Inc. from 1995 to 2003. From 2007 to 2013, she was the President-Human Genetic Therapies Division of Shire Plc and the President of Shire Human Genetic Therapies, Inc.Dr. Grégoire obtained a doctorate degree from the State University of New York at Buffalo in 1986. She also holds an undergraduate degree from Université Laval, conferred in 1984, and an undergraduate degree from Séminaire de Sherbrooke, conferred in 1980. |
